Adonis A Protopapas

Dr. Adonis A Protopapas

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018
Verified
Journal Article
Closed access
DSD Stogiannou
D Stogiannou
APAdonis A Protopapas
Adonis A Protopapas
APAndreas Protopapas
Andreas Protopapas
KTK Tziomalos
K Tziomalos

1 January 2019 in Annals of Gastroenterology
Verified
Journal Article
Open access
APAdonis A Protopapas
Adonis A Protopapas
According to the Baveno VI workshop, patients with compensated advanced liver disease, platelet count (PLT) >150,000/μL and liver stiffness measurement (LSM) 12 kPa) and evaluated them according to the Baveno VI criteria. Exclusion criteria were splanchnic vein thrombosis, use of β-blockers, and esophageal varices. Screening endoscopy was conducted within 6 months of liver stiffness and laboratory measurements. One-hundred seven consecutive patients were enrolled in the study to undergo LSM and screening endoscopy. Of these, 13 met the Baveno VI criteria (12.1%); none of the latter had HRVs. Additional parameters were examined, among which the quotient PLT/log10LSM exhibited the largest area under the curve; concerning the latter, values ≤122,000 μL-1 x kPa-1 predicted high-risk varices with 100% sensitivity and negative predictive value (NPV), preventing 20.6% of patients from unneeded screening endoscopy (P=0.003). Moreover, values ≤92,000 μL-1 x kPa-1 exhibited 86% sensitivity and 94% NPV, preventing 44.9% of patients from unneeded screening endoscopy (P=0.001), while maintaining a tolerable percentage of overlooked patients with HRVs (6.3%). The Baveno VI criteria were successfully validated in our study. The quotient PLT/log10LSM can be used to further decrease the number of screening endoscopies in patients with advanced liver disease.

6 November 2023 in Medicina
Verified
Journal Article
Open access
PDF file
Daniel ParamythiotisDaniel Paramythiotis
Daniel Paramythiotis
Eleni KarlaftiEleni Karlafti
Eleni Karlafti
Matthaios DidagelosMatthaios Didagelos
Matthaios Didagelos
MFMaria Fafouti
Maria Fafouti
KVKalliopi Veroplidou
Kalliopi Veroplidou
Christos SavopoulosChristos Savopoulos
Christos Savopoulos
The emergence of post-COVID-19 syndrome (PCS), a complex and multifactorial condition that follows the acute COVID-19 infection, has raised serious concerns within the global medical community. Concurrently, Irritable Bowel Syndrome (IBS), a widespread chronic gastrointestinal (GI) dysfunction, is considered to be one of the most common disorders of gut–brain interaction (DGBI) that significantly affects the quality of life and social functioning of patients. PCS presents a wide range of symptoms and GI manifestations, including IBS. This review aims to analyze the GI involvement and the prolonged symptoms of COVID-19 infection as part of PCS, in order to explore the potential development of post-infection IBS (PI-IBS) in COVID-19 patients. Irritating factors such as enteric infection, psychosocial conditions, food antigens, and antibiotics may lead to abnormalities in the physiological function of the GI system and could be involved in the development of PI-IBS. Through the presentation of the pathophysiological mechanisms and epidemiological studies that assessed the prevalence of IBS as part of PCS, we attempted to provide a better understanding of the long-term consequences of COVID-19 and the pathogenesis of PI-IBS. Even though PI-IBS is becoming a global challenge, there are only a few studies about it and therefore limited knowledge. Currently, the majority of the existing treatment options are referred to non-COVID-19-associated DGBIs. Forthcoming studies may shed light on the mechanisms of PI-IBS that could be targeted for treatment development.

17 September 2015 in Scientifica
Verified
Journal Article
Open access
PDF file
Georgios LabirisGeorgios Labiris
Georgios Labiris
MFMichael Fanariotis
Michael Fanariotis
CKCatherine Kastanioti
Catherine Kastanioti
GAGeorgios Alexias
Georgios Alexias
APAdonis A Protopapas
Adonis A Protopapas
DNDimitris Niakas
Dimitris Niakas
Purpose.To assess the beliefs and preferences of Greek physicians, regarding generic drugs, in the years of financial crisis.Setting.Multicentered, nationwide survey.Material and Methods.A custom questionnaire based on former similar studies was developed and administered to Greek physicians. The variable “perception on generics” was constructed after an exploratory study and the instrument was validated by conventional and Rasch analysis methods. 22 items formed 5 subscales that constructed the variable in question.Results.908 physicians successfully participated in the study (response rate: 80%). Mean total scores to the instrument were 60.63 ± 12.12 for men and significantly less (58.24 ± 11.73) for women (p= 0.04). Greek physicians were not persuaded on the potential economic gain (45.79 ± 10.53); moreover they identified that Greek authorities cannot address the increased pharmacovigilance mandates. Physicians working in Athens and those working in surgical units demonstrated significantly worse scores than their colleagues from the rest of Greece and those working in Internal Medicine wards (p= 0.03). Conclusion. Our results suggest an overall poor acceptance of the national initiative on generic drugs by Greek physicians. This trial is registered with Clinicaltrials.gov identifier:NCT01855802.

24 March 2023 in Digestive Diseases and Sciences
Verified
Journal Article
Open access
PDF file
APAdonis A Protopapas
Adonis A Protopapas
CSChristos Savopoulos
Christos Savopoulos
LSLemonia Skoura
Lemonia Skoura
IGIoannis Goulis
Ioannis Goulis
Concepts regarding the status of the coagulation process in cirrhosis are rapidly changing. Instead of a disease defined by excessive bleeding risk, recent studies have shown cirrhosis to be associated with a fragile state of rebalanced hemostasis, easily swayed in either direction, thrombosis, or bleeding. These findings, combined with the ever-growing population of patients with cirrhosis with an indication for anticoagulation (AC) and the emergence of the non-alcoholic fatty liver disease epidemic, have prompted a reexamination of the use of AC in patients with cirrhosis, either as a treatment for a concurrent thrombotic disorder or even as a possible therapeutic option that could influence the natural course of the disease and its complications. In recent years, a significant number of studies have been formulated to evaluate these possibilities. These studies evaluated, among others, the efficacy and safety of AC in thrombotic disorders or thrombotic complications of cirrhosis, its effect on survival, and the class of anticoagulants which is more suitable for patients with cirrhosis, depending on disease severity. This review examines recent studies investigating the use of AC in patients with cirrhosis and attempts to provide a simple guide for clinicians regarding the use of AC in patients with cirrhosis and its potential risks and benefits.

17 July 2019 in Lung
Verified
Journal Article
Closed access
PDF file
APAdonis A Protopapas
Adonis A Protopapas
SVStergios Vradelis
Stergios Vradelis
TKTheodoros Karampitsakos
Theodoros Karampitsakos
PSPaschalis Steiropoulos
Paschalis Steiropoulos
ACAthanasios Chatzimichael
Athanasios Chatzimichael
EPEmmanouil Paraskakis
Emmanouil Paraskakis